Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.54 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.54 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.50 |
| ▸ | DPP4 | P27487 | 1/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | APAF1 | O14727 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | AGTR1 | P30556 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | SLC6A9 | P48067 | 2/20 | 0.47 |
| ▸ | RAD52 | P43351 | 1/20 | 0.47 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.46 |
| ▸ | MITF | O75030 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2295411 | 1.00 | NPC1 (0.61) | NPC1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL2295415 | 1.00 | NPC1 (0.61) | NPC1CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL1905029 | 0.85 | DPP4 (0.48) | NPC1ALDH1A1DPP4KDM4ELMNA | |
| SCHEMBL1905027 | 0.85 | DPP4 (0.48) | NPC1ALDH1A1DPP4KDM4ELMNA | |
| SCHEMBL2299046 | 0.85 | ALDH1A1 (0.61) | CYP3A4CYP2C9CYP2C19ALDH1A1DPP4 | |
| SCHEMBL2293531 | 0.85 | GPR139 (0.59) | ALDH1A1DPP4KDM4EAPAF1MAPT | |
| SCHEMBL2294465 | 0.85 | GPR139 (0.59) | ALDH1A1DPP4KDM4EAPAF1MAPT | |
| SCHEMBL2293528 | 0.85 | GPR139 (0.59) | ALDH1A1DPP4KDM4EAPAF1MAPT | |
| SCHEMBL2298989 | 0.85 | ALDH1A1 (0.61) | CYP3A4CYP2C9CYP2C19ALDH1A1DPP4 | |
| SCHEMBL2298992 | 0.85 | ALDH1A1 (0.61) | CYP3A4CYP2C9CYP2C19ALDH1A1DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | claimed |
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-20 | — | — | US | disclosed |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | SANOFI-AVENTIS (FR) | 2011-10-13 | — | — | US | disclosed |
| US-7994315-B2 | Intermediate compound for synthesizing pharmaceutical agent and production method thereof | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2011-08-09 | — | — | US | disclosed |
| EP-2221305-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| EP-2221304-A1 | Method for synthesizing intermediate compound for synthesizing a pharmaceutical agent | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-08-25 | — | — | EP | disclosed |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MITSUBISHI TANABE PHARMA CORPORATION (JP) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257392-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | NPC1 1685/4885CYP3A4 672/4885CYP2D6 1386/4885 |
| US-20110251385-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | NPC1 1685/4885CYP3A4 672/4885CYP2D6 1386/4885 |
| US-20090156804-A1 | INTERMEDIATE COMPOUND FOR SYNTHESIZING PHARMACEUTICAL AGENT AND PRODUCTION METHOD THEREOF | MAPT, PSEN1, PSEN2 | NPC1 1685/4885CYP3A4 672/4885CYP2D6 1386/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.